Reprogramming antitumor immunity

Joseph G Crompton; David Clever; Raul Vizcardo; Mahendra Rao; Nicholas P Restifo

doi:10.1016/j.it.2014.02.003

Reprogramming antitumor immunity

Trends Immunol. 2014 Apr;35(4):178-85. doi: 10.1016/j.it.2014.02.003. Epub 2014 Mar 21.

Authors

Joseph G Crompton¹, David Clever², Raul Vizcardo³, Mahendra Rao⁴, Nicholas P Restifo⁵

Affiliations

¹ National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 2QH, UK; Department of Surgery, University of California Los Angeles, Los Angeles, CA 90095, USA.
² National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge CB2 2QH, UK.
³ National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
⁴ Center for Regenerative Medicine, National Institutes of Health, NIH, Bethesda, MD 20892, USA.
⁵ National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Center for Regenerative Medicine, National Institutes of Health, NIH, Bethesda, MD 20892, USA. Electronic address: restifo@nih.gov.

Abstract

Regenerative medicine holds great promise in replacing tissues and organs lost to degenerative disease and injury. Application of the principles of cellular reprogramming for the treatment of cancer, however, is not well established. Here, we present an overview of cellular reprogramming techniques used in regenerative medicine, and within this context, envision how the scope of regenerative medicine may be expanded to treat metastatic cancer by revitalizing an exhausted and senescent immune system.

Keywords: T cell reprogramming; cancer immunotherapy; regenerative medicine.

Published by Elsevier Ltd.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cellular Reprogramming / immunology*
Humans
Immunotherapy / methods*
Neoplasms / immunology*
Regenerative Medicine / methods*
Regenerative Medicine / trends*

Grants and funding

Z99 CA999999/Intramural NIH HHS/United States